Williams L T, Gore T B, Lefkowitz R J
J Clin Invest. 1977 Feb;59(2):319-24. doi: 10.1172/JCI108643.
The molecular basis for the aberrant catecholamine responsiveness of the adenylate cyclase of adrenocortical carcinoma 494 was explored. The adenylate cyclase of this corticosteroid-producing, transplanted, adrenal cancer of the rat was stimulated not only by adrenocorticotropic hormone and fluoride, but also by the beta-adrenergic agonist, isoproterenol. The adenylate cyclase of normal adrenal tissue was unresponsive to isoproterenol. Direct binding studies with the specific high affinity B-adrenergic ligand, (-)[3H]dihydroalprenolol, demonstrated the pressure of 0.094 pmol of specific binding sites per milligram of tumor membrane protein. By contrast, normal adrenal membranes contained too few binding sites to accurately measure and study using these techniques. The tumor binding sites had high affinity for (-)[3H] dihydroalprenolol with an equilibrium dissociation constant of 2.1 nM. Adrenergic agonists competed for the binding sites in an order of potency, [(-) isoproterenol greater than (-) epinephrine (-) norepinephrine], paralleling their order of potency as beta-adrenergic agonists. The beta-adrenergic antagonist, (-) propranolol, competed for binding, causing half-mzximal inhibition of specific binding at a concentration of 6 nM. The alpha-adrenergic antagonist, phentolamine, and several catecholamine metabolites and precursors did not effectively compete for the binding sites at high concentrations. Binding was stereospecific, the (+) stereoisomers of beta-adrenergic agonists and antagonists requiring 40- to 300-fold higher concentrations than the corresponding (-) stereoisomers to half maximally inhibit (-) [3H] dihydroalprenolol binding. These results indicate that adrenocortical carcinoma 494 membranes contain beta-adrenergic receptor-binding sites which are not normally present in membranes of adrenal tissue. These ectopic beta-adrenergic receptors presumably confer on the neoplastic tissue the catecholamine sensitivity of its adenylate cyclase.
对肾上腺皮质癌494腺苷酸环化酶异常的儿茶酚胺反应性的分子基础进行了探索。这种产生皮质类固醇的大鼠移植肾上腺癌的腺苷酸环化酶不仅受到促肾上腺皮质激素和氟化物的刺激,还受到β-肾上腺素能激动剂异丙肾上腺素的刺激。正常肾上腺组织的腺苷酸环化酶对异丙肾上腺素无反应。用特异性高亲和力的β-肾上腺素能配体(-)[³H]二氢阿普洛尔进行的直接结合研究表明,每毫克肿瘤膜蛋白有0.094皮摩尔的特异性结合位点。相比之下,正常肾上腺膜中的结合位点太少,无法用这些技术准确测量和研究。肿瘤结合位点对(-)[³H]二氢阿普洛尔具有高亲和力,平衡解离常数为2.1纳摩尔。肾上腺素能激动剂按效力顺序竞争结合位点,[(-)异丙肾上腺素>(-)肾上腺素>(-)去甲肾上腺素],与其作为β-肾上腺素能激动剂的效力顺序一致。β-肾上腺素能拮抗剂(-)普萘洛尔竞争结合,在浓度为6纳摩尔时引起特异性结合的半数最大抑制。α-肾上腺素能拮抗剂酚妥拉明以及几种儿茶酚胺代谢产物和前体在高浓度时不能有效竞争结合位点。结合具有立体特异性,β-肾上腺素能激动剂和拮抗剂的(+)立体异构体比相应的(-)立体异构体需要高40至300倍的浓度才能半数最大抑制(-)[³H]二氢阿普洛尔的结合。这些结果表明,肾上腺皮质癌494膜含有肾上腺组织膜中通常不存在的β-肾上腺素能受体结合位点。这些异位β-肾上腺素能受体可能赋予肿瘤组织其腺苷酸环化酶的儿茶酚胺敏感性。